9 Meters Biopharma (NMTR) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsTrendsBuy This Stock NMTR vs. GTBP, JAGX, DRMA, SHPH, CNSP, GRI, BDRX, PRFX, RDHL, and QLGNShould you be buying 9 Meters Biopharma stock or one of its competitors? The main competitors of 9 Meters Biopharma include GT Biopharma (GTBP), Jaguar Animal Health (JAGX), Dermata Therapeutics (DRMA), Shuttle Pharmaceuticals (SHPH), CNS Pharmaceuticals (CNSP), GRI Bio (GRI), Biodexa Pharmaceuticals (BDRX), PainReform (PRFX), Redhill Biopharma (RDHL), and Qualigen Therapeutics (QLGN). These companies are all part of the "pharmaceutical products" industry. 9 Meters Biopharma vs. Its Competitors GT Biopharma Jaguar Animal Health Dermata Therapeutics Shuttle Pharmaceuticals CNS Pharmaceuticals GRI Bio Biodexa Pharmaceuticals PainReform Redhill Biopharma Qualigen Therapeutics GT Biopharma (NASDAQ:GTBP) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability. Does the media refer more to GTBP or NMTR? In the previous week, GT Biopharma had 2 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 2 mentions for GT Biopharma and 0 mentions for 9 Meters Biopharma. GT Biopharma's average media sentiment score of 0.96 beat 9 Meters Biopharma's score of 0.00 indicating that GT Biopharma is being referred to more favorably in the media. Company Overall Sentiment GT Biopharma Positive 9 Meters Biopharma Neutral Which has preferable valuation & earnings, GTBP or NMTR? GT Biopharma is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGT BiopharmaN/AN/A-$13.16M-$4.07-0.239 Meters BiopharmaN/AN/A-$43.77M-$3.46N/A Do analysts recommend GTBP or NMTR? GT Biopharma presently has a consensus target price of $11.00, suggesting a potential upside of 1,077.10%. Given GT Biopharma's stronger consensus rating and higher probable upside, equities analysts clearly believe GT Biopharma is more favorable than 9 Meters Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GT Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.509 Meters Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is GTBP or NMTR more profitable? 9 Meters Biopharma's return on equity of -584.97% beat GT Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets GT BiopharmaN/A -1,804.34% -200.12% 9 Meters Biopharma N/A -584.97%-159.45% Do insiders & institutionals have more ownership in GTBP or NMTR? 8.2% of GT Biopharma shares are held by institutional investors. Comparatively, 22.3% of 9 Meters Biopharma shares are held by institutional investors. 3.4% of GT Biopharma shares are held by insiders. Comparatively, 2.4% of 9 Meters Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more volatility & risk, GTBP or NMTR? GT Biopharma has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500. Comparatively, 9 Meters Biopharma has a beta of 1.36, suggesting that its share price is 36% more volatile than the S&P 500. SummaryGT Biopharma beats 9 Meters Biopharma on 8 of the 14 factors compared between the two stocks. Get 9 Meters Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NMTR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NMTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NMTR vs. The Competition Export to ExcelMetric9 Meters BiopharmaBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.04M$155.80M$5.66B$9.84BDividend YieldN/A3.78%3.93%4.04%P/E Ratio0.0041.2983.2726.61Price / SalesN/A5,361.87451.26176.34Price / CashN/A13.1937.7059.65Price / BookN/A71.5210.556.59Net Income-$43.77M-$90.99M$3.27B$266.12M 9 Meters Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NMTR9 Meters BiopharmaN/AN/AN/AN/A$1.04MN/A0.0020GTBPGT Biopharma2.3596 of 5 stars$1.13+3.7%$11.00+873.5%-57.3%$4.02MN/A-0.288News CoverageGap UpJAGXJaguar Animal Health2.1086 of 5 stars$1.77-1.4%$60.00+3,299.4%-94.2%$3.83M$11.69M0.0050Gap UpDRMADermata Therapeutics2.9951 of 5 stars$5.50-5.6%$10.00+81.8%-66.6%$3.81MN/A-0.348News CoverageSHPHShuttle Pharmaceuticals1.4709 of 5 stars$3.39+2.0%N/A-92.8%$3.62MN/A-0.825Upcoming EarningsCNSPCNS Pharmaceuticals1.5819 of 5 stars$6.24-4.6%$300.00+4,706.9%-92.9%$3.57MN/A0.005GRIGRI Bio1.9653 of 5 stars$1.39-3.5%$22.00+1,482.7%-84.6%$3.50MN/A-0.121Gap DownBDRXBiodexa Pharmaceuticals0.6813 of 5 stars$5.61-9.7%N/AN/A$3.48MN/A0.0020Positive NewsPRFXPainReform1.6199 of 5 stars$1.63-6.3%N/A+55.7%$3.28MN/A-0.014RDHLRedhill BiopharmaN/A$1.35-1.8%N/A-84.3%$3.17M$8.04M0.00210QLGNQualigen TherapeuticsN/A$1.87-0.3%N/A-80.6%$3.16MN/A0.0050 Related Companies and Tools Related Companies GTBP Alternatives JAGX Alternatives DRMA Alternatives SHPH Alternatives CNSP Alternatives GRI Alternatives BDRX Alternatives PRFX Alternatives RDHL Alternatives QLGN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NMTR) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMy NEXT $1 Trillion PredictionJames Altucher is making his next trillion-dollar prediction — and this time, it’s not Apple. He believes Elon...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 9 Meters Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 9 Meters Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NMTR Stock Alerts